3D Medicines Inc. (HKG:1244)
Hong Kong · Delayed Price · Currency is HKD 2.470
+0.210 (9.29%)
Sep 18, 2026, 4:08 PM HKT
3D Medicines Revenue
3D Medicines had revenue of 210.52M CNY in the half year ending June 30, 2026, with 1.99% growth. This brings the company's revenue in the last twelve months to 357.44M, down -20.28% year-over-year. In the year 2025, 3D Medicines had annual revenue of 356.09M, down -20.10%.
Revenue (ttm)
357.44M CNY
Revenue Growth
-20.28%
P/S Ratio
1.47
Revenue / Employee
2.21M CNY
Employees
162
Market Cap
607.42M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 356.09M | -89.56M | -20.10% |
| Dec 31, 2024 | 445.65M | -189.30M | -29.81% |
| Dec 31, 2023 | 634.95M | 67.56M | 11.91% |
| Dec 31, 2022 | 567.39M | 507.13M | 841.57% |
| Dec 31, 2021 | 60.26M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| Cutia Therapeutics | 383.95M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 72.52M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |
| Cloudbreak Pharma | 2.11M |